Gene therapy for esophageal carcinoma: The use of an explant model to test adenoviral vectors ex vivo

Cancer Gene Therapy

Volumn 11, Issue 4, 2004, Pages 289-296

  Marsman, Willem A ^a   Buskens, Christianne J ^a   Wesseling, John G ^a   Offerhaus, G Johan A ^a   Bergman, Jacques J G H M ^a   Tytgat, Guido N J ^a   Van Lanschot, J Jan B ^a   Bosma, Piter J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adenovirus; Barrett esophagus; Esophageal cancer; Explant; RGD

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; RECOMBINANT DNA; ARGINYL-GLYCYL-ASPARTIC ACID; CAR RECEPTOR; OLIGOPEPTIDE; VIRUS RECEPTOR;

ARTICLE; CARCINOMA CELL; CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; EX VIVO STUDY; EXPLANT; GENE THERAPY; HISTOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTESTINE METAPLASIA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SQUAMOUS EPITHELIUM; VIRUS FIBER; ADENOVIRUS; BARRETT ESOPHAGUS; CARCINOMA; ESOPHAGUS TUMOR; FLOW CYTOMETRY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNOCHEMISTRY; METABOLISM; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE;

ADENOVIRIDAE; BARRETT ESOPHAGUS; CARCINOMA; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOCHEMISTRY; OLIGOPEPTIDES; RECEPTORS, VIRUS; TRANSDUCTION, GENETIC;

EID: 3042526896     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700680     Document Type: Article

References (26)

1. Botterweck AA, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. 2000;29:645-654.
2. Daly JM, Fry WA, Little AG, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000;190:562-572; Discussion 572-563.
3. Sagar PM, Gauperaa T, Sue-Ling H, et al. An audit of the treatment of cancer of the oesophagus. Gut. 1994;35: 941-945.
4. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg. 2001;88:338-356.
5. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med. 1985;313:857-859.
6. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg. 1996;224:66-71.
7. Lambert R. Endoscopic treatment of esophagogastric tumors. Endoscopy. 1998;30:80-93.
8. Gomez-Navarro J, Curiel DT, Douglas JT. Gene therapy for cancer. Eur J Cancer. 1999;35:2039-2057.
9. Wadhwa PD, Zielske SP, Roth JC, et al. Cancer gene therapy: scientific basis. Annu Rev Med. 2002;53:437-452.
10. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther. 1998;9:1083-1092.
11. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320-1323.
12. Krasnykh V, Dmitriev I, Mikheeva G, et al. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol. 1998;72:1844-1852.
13. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998;72:9706-9713.
14. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol. 1995;3:207-220.
15. Rockett JC, Larkin K, Darnton SJ, et al. Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer. 1997;75: 258-263.
16. Nishihira T, Kasai M, Mori S, et al. Characteristics of two cell lines (TE-1 and TE-2) derived from human squamous cell carcinoma of the esophagus. Gann. 1979;70:575-584.
17. Trier JS. Organ culture of the mucosa of human small intestine. Methods Cell Biol. 1980;21B:365-384.
18. Rauen KA, Sudilovsky D, Le JL, et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res. 2002;62:3812-3818.
19. Croyle MA, Walter E, Janich S, et al. Role of integrin expression in adenovirus-mediated gene delivery to the intestinal epithelium. Hum Gene Ther. 1998;9:561-573.
20. Hauri HP, Kedinger M, Haffen K, et al. Organ culture of human duodenum and jejunum. Biol Gastroenterol (Paris). 1975;8:307-319.
21. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000;118:487-496.
22. Kaur BS, Ouatu-Lascar R, Omary MB, et al. Bile salts induce or blunt cell proliferation in Barrett's esophagus in an acid-dependent fashion. Am J Physiol Gastrointest Liver Physiol. 2000;278:G1000-G1009.
23. Fitzgerald RC, Omary MB, Triadafilopoulos G. Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett's esophagus. Am J Physiol. 1998;275:G47-G55.
24. Racker E. Why do tumor cells have a high aerobic glycolysis? J Cell Physiol. 1976;89:697-700.
25. Dobson H, Pignatelli M, Hopwood D, et al. Cell adhesion molecules in oesophageal epithelium. Gut. 1994;35:1343-1347.
26. Walter E, Croyle MA, Roessler BJ, et al. The absence of accessible vitronectin receptors in differentiated tissue hinders adenoviral-mediated gene transfer to the intestinal epithelium in vitro. Pharm Res. 1997;14:1216-1222.